GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures

Plug Pulled After Three Trial Flops

Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.

GSK Exit
GSK is exiting the deal after paying an upfront fee of $360m, but will not have to pay any milestones after bintrafusp's disappointing results.

GlaxoSmithKline has ended its collaboration with Merck KGaA on the oncology asset bintrafusp alfa after a string of clinical trial failures.

GSK paid $360m upfront for a stake in bintrafusp, a bifunctional fusion protein that targets PD-1 and TGF-beta in 2019,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip